Key Points
- Billiontoone SVP Bosch John Roderick Ten sold 1,416 shares for $150,959.76 at an average price of $106.61 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 5.65% to 23,635 shares.
- BLLN opened at $114.42, with a $5.40 billion market capitalization and a 12-month trading range of $61.96 to $150.44. The company recently reported quarterly revenue of $109.45 million and earnings of $0.15 per share, in line with estimates.
- Analyst sentiment is mixed: seven analysts rate the stock a Buy, two rate it Hold and two rate it Sell, resulting in a consensus Hold rating and an average price target of $125.88.
Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) SVP Bosch John Roderick Ten sold 1,416 shares of the business's stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $106.61, for a total transaction of $150,959.76. Following the transaction, the senior vice president owned 23,635 shares in the company, valued at approximately $2,519,727.35. This trade represents a 5.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Bosch John Roderick Ten also recently made the following trade(s):
- On Wednesday, September 9th, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The shares were sold at an average price of $97.54, for a total transaction of $138,116.64.
- On Tuesday, August 25th, Bosch John Roderick Ten sold 1,417 shares of Billiontoone stock. The stock was sold at an average price of $100.00, for a total transaction of $141,700.00.
- On Monday, August 10th, Bosch John Roderick Ten sold 1,417 shares of Billiontoone stock. The stock was sold at an average price of $92.86, for a total value of $131,582.62.
- On Monday, June 29th, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The shares were sold at an average price of $120.00, for a total value of $169,920.00.
Billiontoone Stock Performance
Shares of BLLN opened at $114.42 on Thursday. The company has a current ratio of 11.69, a quick ratio of 11.31 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $5.40 billion and a price-to-earnings ratio of 163.46. The stock has a 50 day moving average of $108.94 and a 200 day moving average of $97.79. Billiontoone, Inc. has a 12 month low of $61.96 and a 12 month high of $150.44.
Billiontoone (NASDAQ:BLLN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, hitting the consensus estimate of $0.15. The business had revenue of $109.45 million for the quarter. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%. As a group, sell-side analysts forecast that Billiontoone, Inc. will post 0.83 earnings per share for the current year.
Hedge Funds Weigh In On Billiontoone
A number of institutional investors have recently added to or reduced their stakes in BLLN. The Manufacturers Life Insurance Company raised its holdings in shares of Billiontoone by 151.8% in the 1st quarter. The Manufacturers Life Insurance Company now owns 30,506 shares of the company's stock valued at $2,408,000 after acquiring an additional 18,389 shares in the last quarter. Sei Investments Co. bought a new position in shares of Billiontoone in the first quarter worth approximately $1,058,000. Wasatch Advisors LP increased its position in shares of Billiontoone by 40.2% in the second quarter. Wasatch Advisors LP now owns 518,084 shares of the company's stock worth $62,160,000 after purchasing an additional 148,446 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its stake in Billiontoone by 11.9% in the first quarter. Emerald Mutual Fund Advisers Trust now owns 132,206 shares of the company's stock valued at $10,436,000 after purchasing an additional 14,072 shares in the last quarter. Finally, Perceptive Advisors LLC lifted its position in Billiontoone by 26.1% during the first quarter. Perceptive Advisors LLC now owns 91,812 shares of the company's stock valued at $7,248,000 after purchasing an additional 19,000 shares during the last quarter.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on BLLN shares. Guggenheim initiated coverage on Billiontoone in a research report on Monday, June 29th. They issued a "buy" rating and a $125.00 price target for the company. Weiss Ratings reissued a "sell (d+)" rating on shares of Billiontoone in a report on Friday, September 18th. Zacks Research lowered Billiontoone from a "hold" rating to a "strong sell" rating in a report on Monday, August 31st. JPMorgan Chase & Co. decreased their price target on Billiontoone from $145.00 to $130.00 and set an "overweight" rating on the stock in a research report on Thursday, August 6th. Finally, Canaccord Genuity Group began coverage on shares of Billiontoone in a report on Wednesday, September 2nd. They issued a "buy" rating and a $120.00 price target on the stock. Seven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Billiontoone presently has a consensus rating of "Hold" and an average target price of $125.88.
Check Out Our Latest Research Report on Billiontoone
Billiontoone Company Profile
(
Get Free Report)
BillionToOne, Inc is a molecular diagnostics company that develops blood-based tests designed to provide genetic and health information from small amounts of biological material. The company's technology uses its proprietary quantitative counting template approach to improve the accuracy and sensitivity of molecular testing.
The company's primary offerings include UNITY, a portfolio of prenatal genetic tests. These services support screening for chromosomal conditions, single-gene disorders and carrier status, and are designed to help healthcare providers assess fetal and maternal genetic risks using a maternal blood sample.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
